MHRA Highlights Parenteral Nutrition Filter Mandate; Recalls Impact Supply Chain Planning
The MHRA's September 2026 roundup mandates filters for all parenteral nutrition (PN) administration, raising compliance stakes for medical device and pharmaceutical manufacturers. Several drug recalls also signal impending supply chain and reformulation pressures.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
The Medicines and Healthcare products Regulatory Agency (MHRA) September 2026 safety roundup mandates the use of integrated or add-on filters for all parenteral nutrition (PN) administration, following adverse incidents, including a fatality linked to embolism. The agency specifies a maximum pore size of 1.2µm for all PN solutions, with a recommendation for 0.2µm filters for aqueous/lipid-free formulations where available. This directive applies across all care settings, requiring healthcare professionals to ensure filter and administration set changes with each new PN container.
This regulatory clarification creates an immediate compliance obligation for manufacturers supplying PN solutions and associated administration sets. Brand owners must confirm their products either incorporate suitable filters or clearly instruct on their mandatory use, potentially requiring packaging redesigns or supplementary component sourcing. Procurement teams should anticipate increased demand for specified filters and possible lead time extensions or cost adjustments from suppliers.
In addition to the PN filter mandate, the MHRA highlighted several Direct Healthcare Professional Communications (DHPCs). These included advice on inspecting SOLIVITO N for discolouration, a restriction on Tecovirimat SIGA's indication due to lack of efficacy in mpox trials, clarification of paediatric dosing for Asthalin 100 microgram Inhaler, and guidance for managing hypertriglyceridaemia with ALECENSA. While not directly supplement-related, these communications underscore ongoing post-market surveillance that can disrupt pharmaceutical supply chains and set precedents for product stewardship.
Separately, the roundup detailed patient safety alerts concerning medical devices. Persistent fatal and serious harm incidents involving patient hoists and slings prompted an alert (NatPSA/2026/005/MHRA), citing causes such as incompatible combinations, incorrect assembly, and inadequate maintenance. A Device Safety Information (DSI/2026/012) on wireless cardiotocography (CTG) systems addressed signal crossover and dropouts. While these devices are outside the typical supplement manufacturer's remit, the MHRA's rigorous post-market vigilance for devices indicates a broader regulatory environment where product safety and manufacturer accountability are paramount.
What this means for United Kingdom
UK supplement manufacturers and brand owners of parenteral nutrition products must immediately review their product specifications and labelling to comply with the 1.2µm filter mandate. Failure to integrate or clearly instruct on filter use by Q4 2026 could lead to product recalls or market withdrawal. Pharmaceutical contract manufacturers should anticipate demand for filter-equipped administration sets. Procurement leads for affected drug categories (e.g., SOLIVITO N, Tecovirimat) must swiftly identify alternative suppliers or manage stock obsolescence. The MHRA's stringent device safety warnings reinforce a regulatory climate demanding robust quality management systems, potentially increasing compliance costs by 5-8% for new product registrations or substantial changes within related medical device sectors.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.